Local view for "http://purl.org/linkedpolitics/eu/plenary/2007-10-23-Speech-2-399"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2007-10-23"^^xsd:date2
dcterms:Is Part Of	lp_eu:Protocol amending TRIPS (debate)2
dcterms:Language	"it"^^xsd:language2
lpv:document identification number	"en.20071023.28.2-399"2
lpv:hasSubsequent	lp_eu:2007-10-23-Speech-2-4002
lpv:speaker	lp:Umberto Guidoni2
lpv:spokenAs	member; Delegation for relations with the United States (2007-03-14--2009-07-13)3 substitute; Temporary Committee on Climate Change (2007-05-10--2009-02-04)3 substitute; Delegation for relations with Japan (2007-03-14--2009-07-13)3 unknown; Partito dei Comunisti Italiani (2004-07-20--2009-07-13)3 member; EUL/NGL (2004-07-20--2009-07-13)3 member; CONT (2007-01-31--2009-07-13)3 substitute; ENVI (2007-01-31--2009-07-13)3 member; ITRE (2007-01-31--2009-07-13)3
lpv:translated text	"Mr President, ladies and gentlemen, the European Parliament has been called upon to express an opinion on whether the amendment to the WTO agreements on intellectual property – the ‘TRIPS Agreements’ – can be made permanent, as this would represent a swift solution to the problem of access to medicines by developing countries. Considering that up to now, this amendment has offered no proof of its real effectiveness, it is important for the European Parliament to seize the opportunity offered by the ratification of the TRIPS amendment to secure greater guarantees that EU policy on access to medicines will be comprehensive, coherent and effective. The TRIPS Agreement, as the Council has recognised, represents only part of the solution to the problem of access to medicines and public health; it is important therefore that the Council, as emphasised several times by Parliament, should declare its support for all those countries who intend to take advantage of the flexibilities offered by the TRIPS Agreements, to be able to provide essential medicines at affordable prices. The European Union must do more to stem the health crisis in the world’s poorest countries, particularly by ensuring that these countries can meet their own needs, without burdening them with bilateral or regional agreements, the ‘TRIPS-plus’ Agreements, on provisions relating to pharmaceutical products that risk having a negative impact on access to public health and medicines. We also believe that it is the task of the Commission and the Council to support WTO initiatives to make TRIPS rules less complex, and specifically to maximise product availability."@en1

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph